ABA Autism denied as experimental or investigational by Molina Healthcare?

EPSDT-mandated coverage for under-21. ASD diagnosis required. Hours per BCBA-developed plan.

EPSDT 42 USC §1396d(r)(5) — Medicaid MUST cover medically necessary services for under-21 regardless of state plan limits. CASP 2020 dosage guidelines: 30-40 hrs/week for early learners. CMS Informational Bulletin July 7, 2014 on ABA under EPSDT.

## Molina Healthcare Denies ABA as "Experimental" — Why This Is Wrong and How to Fight It

If Molina Healthcare has denied Applied Behavior Analysis (ABA) for Autism Spectrum Disorder (ASD) on the grounds that it is experimental, investigational, or unproven, this denial is among the most legally and clinically vulnerable denial types you can receive. ABA has been recognized as an evidence-based treatment for ASD by major medical and governmental bodies for decades.

### Why This Denial Happens

Experimental or investigational denials can result from outdated coverage policies, administrative coding errors, or a plan's failure to update its coverage determinations to reflect the current scientific and regulatory consensus. In some cases, the denial may be triggered by a specific ABA protocol or delivery modality (such as telehealth-based ABA) that the policy has not yet addressed separately from in-person ABA.

### Why It Is Appealable

ABA for ASD is recognized as evidence-based by organizations including the American Academy of Pediatrics, the U.S. Surgeon General, and the National Institutes of Health, among others. It is a covered benefit under federal and most state Medicaid programs precisely because it is not experimental. An "experimental" denial for ABA will almost always fail independent clinical review.

Key legal frameworks supporting your appeal: - ACA Section 2719 — grants the right to independent external review by a certified IRO. The external review window is approximately four months from denial. Expedited review is available when health would be seriously jeopardized by delay. - ERISA Section 503 — requires a full and fair review of all denied claims, including access to the clinical criteria and evidence used. - MHPAEA — prohibits more restrictive coverage standards for mental health/developmental conditions than for comparable medical/surgical benefits.

Request, in writing, the specific clinical evidence Molina relied upon to classify ABA as experimental, along with the name and credentials of the reviewing clinician.

### The Appeal Process

1. Request the complete denial basis — Molina must disclose the evidence and criteria used to classify ABA as experimental. 2. Level 1 internal appeal — file within the timeframe in the denial notice. Include a clinical rebuttal with supporting literature and guidelines. 3. Level 2 internal appeal if Level 1 fails. 4. External review — this denial type is especially strong for IRO review, as independent clinicians are highly unlikely to uphold an "experimental" classification for ABA. 5. State insurance commissioner complaint — if Molina's policy is facially inconsistent with state coverage mandates, a regulatory complaint may run in parallel.

### Documentation to Gather

• ASD diagnosis confirmation — formal diagnostic report from a licensed evaluator.
• BCBA treatment plan — current, individualized plan with specific behavioral goals.
• Prescribing physician letter — confirming ASD diagnosis and supporting ABA as the appropriate standard of care for this patient.
• Evidence support letter — from the BCBA or physician citing the established evidence base for ABA (referencing guideline organizations, not specific trial statistics).
• State mandate research — document any applicable state law or Medicaid coverage rule requiring ABA coverage for ASD.

### Criteria-Mapping Structure

| Molina's Experimental Classification Basis | Appeal Response | |---|---| | Clinical evidence cited by Molina | [Your rebuttal citing recognized guideline organizations] | | Specific ABA protocol flagged | [Documentation that protocol is within standard of care] | | ASD diagnosis and individualized need | [Diagnostic report + BCBA assessment] |

An "experimental" denial for ABA that reaches external review is rarely upheld. File promptly and include the strongest possible clinical evidence summary from the treating team.